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ABSTRACT 
Sarah Ann Delaplane 
 
MASS SPECTROMETRIC APPROACHES 
TO PROBING THE REDOX FUNCTION 
OF APE1 
 
Human apurinic/apyrimidinic endonuclease 1 (hApe1) is a multi-functional 
protein having two major functions: apurinic/apyrimidinic endonuclease activity for 
DNA damage repair and redox activity for gene regulation. Many studies have shown the 
action of Ape1 in the base excision repair pathway leading to cell survival. It has also 
been reported that Ape1 reduces a number of important transcription factors that are 
involved in cancer promotion and progression. Though the repair activity is well 
understood, the redox mechanism is not yet clear.  
What is known about Ape1 is its structure and that it contains seven cysteines 
(C65, C93, C99, C138, C208, C296, and C310), none of which are disulfide bonded. Two 
of these cysteines, C99 and C138, are solvent-accessible, and C65, C93, and C99 are 
located in the redox domain. It is believed that one or more cysteines are involved in the 
redox function and is hypothesized that hApe1 reduces the down-stream transcription 
factors by a disulfide exchange mechanism.  
E3330, (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquninoyl)]2-nonyl-2-
propenoic acid, is a specific inhibitor for the redox function of hApe1. The interaction 
mechanism is not known. Using N-Ethylmaleimide (NEM) chemical footprinting, 
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combined with Hydrogen/Deuterium Exchange (HDX) data, we propose that a locally 
unfolded form coexists with the folded form in an equilibrium that is driven by 
irreversible NEM labeling, and that E3330 interacts with and stabilizes this locally 
unfolded form. This locally unfolded form is thereby proposed to be the redox-active 
form. We further support this claim with LC-MS/MS analysis showing an increase of 
disulfide bonds induced by E3330 among the cysteines in the redox domain, which would 
be too far apart from each other in the folded form to form a disulfide bond.   
We also studied three analogs of E3330. The need for an E3330 analog is to 
develop a more efficient and effective compound that would allow for sub-micromolar 
levels of activity (E3330 requires a micromolar amount). Study of the analogs will also 
allow us to gain perspective of the mechanism or mechanisms of E3330’s activity in 
Ape1’s redox function. 
 
     Millie M. Georgiadis, Ph.D., Committee Chair
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CHAPTER I 
Overview of Ape 
 
Introduction of Ape1 Function 
Human apurinic/apyrimidinic endonuclease 1 (hApe1) is a multi-functional 
protein having two major functions: apurinic/apyrimidinic endonuclease activity for 
DNA damage repair and redox activity for gene regulation (1). Not only is Ape1 involved 
in vital functions, its importance to the cell is that there is no backup for its 
responsibilities. This is demonstrated by the fact that it has not been possible to generate 
an animal knockout model. Ape1 mouse knockouts are embryonic lethal, and no viable 
cell lines have been established that are completely deficient for Ape1 (2). 
 It had been reported that Ape1’s redox and repair domains were separate: redox 
within the N-terminal and repair within the C-terminal regions (3). However, these 
functional domains do not coincide with the structural domains of the protein. A recent 
review of Ape1 (1) discusses the structural similarities in regard to topology and 
endonuclease activity sites between hApe1 and E. coli exonuclease III (the AP 
endonuclease found within E. coli); however, redox function is only found in mammals. 
Human Ape1 does have an additional 62 N-terminal residues, but these alone cannot be 
responsible for redox activity considering that zebrafish also has the additional N-
terminal residues and no redox activity. What is needed for hApe1 redox function 
remains a question worth investigating. 
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Ape1 in the Base Excision Repair Pathway 
DNA damage can occur from of variety of sources, including alkylation, 
deamination, and oxidation of bases. Base Excision Repair (BER) is the pathway used for 
repairing this DNA damage (4-6). Alkylation of bases is caused by exposure to either 
endogenous or exogenous agents. Another source, deamination of cytidines and adenines, 
occurs spontaneously. DNA damage can also be due to reactive oxygen species in normal 
cellular processes or environmental or chemotherapeutic agents. BER is needed for 
repairing DNA damage caused by these sources, and Ape1 plays a key, irreplaceable role 
in it. Ape1 is needed in the second step of the base excision repair (BER) pathway to 
cleave the phosphodiester bond 5’ of an abasic site (or AP site) (Figure 1). Abasic sites 
are generated by DNA glycosylases, which excise a base damaged by alkylation or 
oxidation, and then subsequently processed by Ape1, leaving a 3'-OH and 5'-deoxyribose 
phosphate (7-9). DNA glycosylases, both monofunctional and bifunctional, initiate BER 
by recognizing oxidized or alkylated bases. The monofunctional form excises the 
damaged base creating an abasic site, which is the site that Ape1 acts upon. Bifunctional 
glycosylases excise the damaged base and nick the phosphodiester backbone 3’ to the AP 
site. Ape1 then hydrolyzes the phosphodiester backbone 5’ to the AP site creating 3’ OH 
and 5’ deoxyribose phosphate (5’ dRP) ends (10, 11) (Figure 2), which are processed by 
subsequent enzymes of the BER pathway. Without the removal of a damaged base 
resulting in an AP site, there could be a block to DNA replication and genetic instability 
(12). Ape1 is responsible for 95% of the endonuclease activity in the cell (7, 8), and there 
is no replacement for its function. Therefore, Ape1 is vital for survival. Ape1 is also 
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responsible for recruiting other DNA repair proteins for BER through protein-protein 
interactions and indirect interactions (1). 
 
Ape1’s Redox Function 
The search for Ape1’s redox function begins with an attempt to identify the 
nuclear factor responsible for reducing transcription factor Activator protein-1 (AP-1). 
Fos and Jun were shown to form a heterodimeric complex that binds to transcriptional 
control elements containing AP-1 binding sites that regulate gene expression (13). Cell 
growth and differentiation are controlled through the regulation of gene expression by 
extracellular signals. 
In early experiments, as well as the ones we are currently employing, cysteine 
residues were being monitored. Cysteine residues are often required for functional and 
structural properties of proteins and can be used to define characteristic protein domains. 
Usually cysteine residues are conserved across phylogenetic boundaries and among gene 
families (14). It was shown that reduction of a conserved cysteine residue in the DNA-
binding domains of Fos and Jun by chemical reducing agents or by a nuclear redox factor 
stimulates DNA-binding activity. Ape1 was first identified and characterized as this 
nuclear factor, termed as a redox effector factor-1 (Ref-1) (15, 16). Ref-1 stimulates AP-1 
DNA-binding activity in Fos and Jun through a mechanism involving the conserved Cys 
residues. It did not alter the DNA-binding specificity of Fos and Jun, which begun an 
examination of a novel redox component of the signal transduction processes that 
regulates eukaryotic gene expression. 
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These studies led to the identification of a redox mechanism that is required to 
modulate AP-1 DNA binding activity in vitro (15, 17). Redox regulation was mediated 
by a conserved cysteine residue located in the DNA-binding domains of Fos and Jun that 
was flanked by basic amino acids (17). Fos and Jun could be converted to an inactive 
state by chemical oxidation or modification of this residue (18). At that time, there was a 
lot of debate on the role of redox switching in regulating transcription factor function 
because of the generally accepted view that the intracellular environment is reducing and 
very little was known about the redox environment of the nucleus.  
After the discovery of Ref1’s involvement in reducing AP-1, the enzyme was 
later identified as Ape1 (14). Since the initial discovery of reducing AP-1, Ape1 has been 
reported to reduce a number of other important transcription factors including NFĸB, 
p53, PAX, and others (19-25) (Figure 3). The redox activity of Ape1 plays an important 
role in regulating the expression of a large number of DNA repair proteins. The 
mechanism of hApe1 in the reduction of transcription factors is unclear. 
 
Exposing Redox Function Through Structure 
Human Ape1 contains seven cysteines (C65, C93, C99, C138, C208, C296, and 
C310). Two of these (C99 and C138) are solvent-accessible, as shown in the crystal 
structure (Figure 4) (26-29). Three cysteines, C65, C93, C208, are buried in Ape1’s core. 
Not only does the structure show no disulfide bonds, there are no cysteines within range 
to allow for a disulfide bond. Cysteine 93 and C208 are the two cysteines that reside 
closest to one another, but their sulfur atoms remain 3.5 Å apart (typically a disulfide 
bond is no longer than 2.2 Å).  
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Investigating Cys residues within Ape1 was based on the finding that a cysteine 
residue within the DNA-binding domain of the transcription factor c-Jun was subject to 
oxidation leading to loss of DNA-binding and was reduced by Ape1 (14, 17, 30). 
Because Ape’s redox activity is unique to the mammalian form (unlike endonuclease 
activity which is also seen in all organisms, including bacteria), C65 became a focus 
because it is also unique to mammals (29).  
In a study employing both site-directed mutagenesis and in vitro electrophoretic-
mobility-shift-assay (EMSA) analysis, the role of cysteine residues in Ape1’s redox 
activity has been previously investigated by mutating each of the cysteines to an alanine. 
Of Ape1’s seven cysteines, only C65A was found to be redox inactive (31). 
Only one publication (32) reported that C65 was not an essential residue. This 
study reported a viable C64A (64 in mouse is equivalent to 65 in human) knock-in 
mouse, which challenged the importance of this residue for cell survival. This finding 
was counter challenged by another study that examined the role of Cys65 in the redox 
activity of Ape1 using zebrafish, which is 65% identical to human Ape1. In looking at the 
structures, the zebrafish structure is similar to human Ape1 with five of the seven 
cysteines found in mammalian Ape1 being conserved (29). The two that are not 
conserved are Cys65 and Cys138. Analysis of the Cys residues within vertebrates 
suggests that the presence of Cys65 is unique to mammals and distinguishes their Ape1 
from that in nonmammalian vertebrates (29). The zebrafish Ape (zfApe) contains the 
catalytic residues for its endonuclease activity but instead of including a cysteine at the 
65 position, it has Thr58. A T58C zfApe mutant was made and tested for redox activity 
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along with a native zfApe sample. The native zfApe was inactive for redox activity; 
however, the mutant T58C zfApe was as active as the human Ape1 (29).  
This evidence shows the importance of the Cys65 in the redox activity of Ape1. 
How this cysteine is made accessible to the transcription factors is unknown. Again, the 
crystal structures show that Cys65 is buried within the protein and not accessible to any 
transcriptional factors, implying that Ape1 would have to undergo a conformational 
change. 
 
Ape1’s Role as a Cancer Therapeutic 
It is recognized that DNA-damaging agents are useful in killing cancer cells (33). 
The up regulation or activation of a number of different pathways that cause resistance of 
the cancer cells to the treatment with DNA damaging agents is a problem. Pathways 
included are those involved in signaling, multidrug resistance, cell-cycle checkpoints, 
antiangiogenesis, and others as potential approaches to treat and kill cancer. There has 
been a focus on blocking the ability of a cancer cell to recognize and repair the damaged 
DNA that results from front-line cancer treatments, chemotherapy, and radiation. One of 
these systems includes DNA-repair enzymes, such as Ape1, leading to resistance and 
failure of the agent to kill the cancer cells (6, 34). One possible strategy for preventing 
resistance and improving efficacy of the DNA-targeting agents would be to inhibit the 
DNA-repair enzyme responsible for resistance.  
Another approach, that has not been extensively studied, is targeting the redox 
function of Ape1 to prevent cell proliferation. Intracellular redox has been suggested as a 
regulator of growth in cancer cells (35). Ape1 is overexpressed in numerous cancers, 
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including prostate and bladder cancers (36, 37). In these and other studies, Ape1 
overexpression is associated with an adverse prognosis (36) and/or resistance to radiation 
and chemotherapeutic agents (38).    
Regulation of the intracellular redox environment is critical for cell viability and 
maintenance of cellular homeostasis. An Ape1 deficient cell line cannot be generated 
because Ape1 is essential for early embryonic development in mice (39). Therefore 
identification and development of a specific inhibitor of this protein will significantly 
help as a tool in Ape1 functional study and therapeutic potential.  
Both of Ape1’s functions (endonuclease and redox) can be used in developing 
inhibitors as potential cancer therapeutics. We focused on blocking the redox function of 
Ape1. These studies are divided into two parts. The first is development of a recent novel 
approach to cancer therapeutic agents targeting the redox activity of hApe1 (1, 40). A 
quinone derivative E3330, (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4-benzoquninoyl)]2-
nonyl-2-propenoic acid, was found to inhibit specifically the redox ability of hApe1 (41-
44). E3330 is able to kill a variety of cancer cells but does not significantly affect normal 
cells (1). Using this inhibitor, we conducted a series of experiments to elucidate the Ape1 
redox mechanism (45). 
The second chapter includes a characterization of analog compounds of E3330: 
RN7-60, RN8-51, and RN10-52. These compounds were studied in a recent publication 
(46), and further investigation is required to determine their value as redox inhibitors. 
The need for an E3330 analog is to develop a more efficient and effective compound that 
would allow for sub-micromolar levels of activity (E3330 requires a micromolar 
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amount), and to gain perspective of the mechanism or mechanisms of E3330’s activity in 
Ape1’s redox function. 
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CHAPTER II 
E3330 Studies 
 
Interaction of E3330 with Ape1 
E3330 (Figure 5), a quinone derivative, is otherwise known as 2E)-3-[5-(2,3-
dimethoxy-6-methyl-1,4-benzoquninoyl)]2-nonyl-2-propenoic acid. It was found to 
inhibit specifically the redox ability of hApe1 without affecting its endonuclease activity 
(42-44, 47). E3330 is able to kill a variety of cancer (i.e., ovarian, colon, lung, breast, 
brain, pancreatic, prostate, multiple myeloma) cells but does not significantly affect 
normal cells (41). No studies have successfully shown the mechanism by which E3330 
inhibits Ape1’s redox activity. There’s yet to be confirmation of the location of the 
binding site and the conformational changes, if any, associated with hApe1 binding to 
E3330. 
Earlier studies separated Ape1 from Jurkat cell extract on beads tagged with 
E3330, making Ape1 the primary target of E3330 (41). Using surface Plasmon resonance 
(SPR), it was reported that the binding constant for hApe1 and E3330 is 1.6 nM, which 
indicates strong and specific binding between hApe1 and E3330. Further studies showed 
E3330’s ability to block Ape1 from reducing NFĸB, prohibiting redox activity (48). 
Previous studies of E3330 show an inhibition of Ape1’s redox activity (44). 
Furthermore, it was demonstrated that the humanized zebrafish Ape1, previously 
demonstrated to gain redox activity (29), was also inhibited by E3330 (44). This study 
also showed that the inhibition of the redox activity of Ape1 had no effect on Ape’s 
repair function. 
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E3330 was also able to block the redox function of Ape1 in two ovarian cancer 
cell lines by using a transactivation reporter assay in a dose-dependent manner (44). This 
data shows the role of Ape1 in redox activation of downstream targets, and it 
demonstrates that E3330 is a small molecule that blocks transcription-factor activation. 
Of particular interest are the transcription factors that are involved in cancer cell growth 
and proliferation, such as NFĸB and AP-1.  
Other studies demonstrated that blocking the redox function of Ape1 led to 
blocking cell proliferation (42). The benefit of using E3330 to approach the redox 
function of Ape1 is that it doesn’t use the overexpression of Ape1, Ape1 antisense 
oligonucleotides, or Ape1 siRNA, as reported in studies had that showed altering Ape1 
levels leads to blockage of cell growth and increased cancer cell sensitivity (6, 38, 49-
57). The approaches from those studies caused a change in the total cellular content level 
of Ape1 and, in the case of antisense or siRNA, removed all of the Ape1 functions, not 
just the repair or redox activities. Because Ape1 has multiple functions as well as 
protein–protein interactions with other DNA repair and signaling proteins, the increase or 
decrease of Ape1 protein may result in inaccurate findings. Use of specific small-
molecule inhibitors of Ape1 redox activity, like E3330, focuses on the exact role of 
native levels of Ape1 in various cancer, disease, and normal cellular functions.  
To help understand the redox activity of Ape1 with important transcription 
factors, the inhibitory activity of E3330 was examined. A crystal structure of an 
Ape1/E3330 complex has yet to be solved, and so a different approach was pursued in 
this study.   
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In an effort to detail further the redox mechanism, we developed a chemical 
footprinting/mass spectrometric assay using N-ethylmaleimide (NEM) (Figure 5), an 
irreversible cysteine modifier, to characterize the interaction of the redox inhibitor, 
E3330, with Ape1. NEM is a water-soluble, small molecule that specifically reacts with 
solvent-accessible cysteines via a Michael addition. This modification is irreversible. 
This reagent is widely used in protein footprinting (58-61). Our results show an 
interaction between E3330 and Ape1 and provide new information on the redox 
mechanism of Ape1. 
 
Material and Methods 
Compound 
E3330 was synthesized as previously described (44).  
 
Expression and purification of proteins 
wtΔ40APE1 
A truncated Ape, hΔ40Ape1 (40-318), was cloned into pet28a vector using 
BamH1 and XhoI restriction sites with an N-terminal hexa-His affinity tag , then 
transformed into Rosetta (DE3) E. coli (Novagen). The cells were grown in 6 L of LB 
media with 100 µg/mL kanamycin and 34 µg/mL chloramphenicol until the OD at 600 
nm reached 0.5, and then induced for 4 hours with 1 mM IPTG at 37ºC. The cultures 
were harvested by centrifugation at 4000 × g for 30 minutes, and the pellets were stored 
at -80ºC. The cell pellets were each resuspended in 20 mL of 50 mM sodium phosphate 
buffer pH 7.8, 0.3 M NaCl, 10 mM imidazole, and then lysed by using a French press 
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(SLM-AMINCO, Spectronic Instruments, Rochester, NY) at 1000 psi. The suspension 
was centrifuged at 35,000 rpm for 35 min, and the supernatant was then loaded on a Ni-
NTA column at 4ºC. The protein was eluted with a linear imidazole gradient (0.02– 0.5 
M), and fractions containing hΔ40Ape1 were further purified on an S-Sepharose column 
using 50 mM MES pH 6.5, 1 mM DTT, and a linear NaCl gradient (0.05–1 M). The 
fractions were incubated overnight with 2 units/mg of thrombin to cleave the N-terminal 
hexa-His tag and then subjected to a final S-Sepharose chromatographic purification step. 
Fractions containing hΔ40Ape1 were then concentrated using Amicon Ultra centrifugal 
concentrators (Millipore, Billerica, MA) and stored at -80ºC. Site-directed mutagenesis 
using the Stratagene Quikchange kit (La Jolla, CA) was used to introduce C99A, C138A, 
and C99A/C138A substitutions in hΔ40Ape1.  
Primers for mutation: 
C99A  5’—CAAGAGACCAAA GCC TCAGAGAACAAACTACCAGC—3’ 
 3’—GTTCTCTGGTTT CGG AGTCTCTTGTTTGATGGTCG—3’  
C138A 5’—GGCCTGCTTTCCCGCCAG GCC CCACTCAAAGTTTCTTACGGC—3’ 
 3’—CCGGACGAAAGGGCGGTC CGG GGTGAGTTTCAAAGAATGCCG-3’  
Substituted hΔ40Ape1 proteins were expressed and purified as described for wtΔ40Ape1 
and confirmed by DNA sequencing analysis.    
 
Mass Spectrometric Analysis 
NanoESI (nESI) MS  
40Ape1 was incubated in 1 M ammonium acetate (pH 7.5) with or without 
E3330 at room temperature (RT) for 4 h. Protein samples were analyzed by nESI-MS in 
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the positive-ion mode on a Bruker MaXis UHR-TOF (ultra-high resolution time-of-
flight) (Bruker Daltonics Inc., Fremont, CA) at a flow rate of 25 nL/min. The capillary 
voltage was set at -(1000-1200 V). Dry gas and temperature were at 5.0 L/min and 50ºC, 
respectively. The instrument was externally calibrated by using ―Tuning Mix‖ (Agilent 
Technologies, Santa Clara, CA). The spray tips were made in-house by pulling a 150 µm 
i.d. × 365 µm o.d. fused silica capillary with a P-2000 Laser Puller (Sutter Instrument 
Co., Novato, CA). A four-step program was used with the parameter setup as follows 
with all other values set to zero: Heat = 290, velocity = 40, delay = 200; Heat = 280, 
velocity = 30, delay = 200; Heat = 270, velocity = 25, delay = 200; Heat = 260, velocity 
= 20, delay = 200. Tips were cut accordingly to allow a good spray under the 
experimental conditions. For each sample, a new tip was used to avoid cross 
contamination.  
 
NEM Chemical Footprinting and ESI-MS 
For NEM labeling, 10-20 µL of 40Ape1/NEM (40Ape1:NEM = 1:5, mol/mol) 
and 40Ape1/NEM/E3330 (40Ape1:NEM:E3330 = 1:5:5, mol/mol/mol) 40Ape1 
samples were incubated in 10 mM HEPES buffer (pH 7.5) at room temperature; the 
protein concentration was 100 µM. At a certain time, a 1 µL aliquot was removed and 
quenched with 1 µL of 20 mM DTT. Mass spectra were collected on the Bruker MaXis 
UHR-TOF or Waters Micromass Q-TOF instrument (Waters Micromass, Manchester, 
UK). The parameters for MaXis mass spectrometer are as follows: Capillary voltage was 
set at -3600 V. Nebulizer pressure was 0.4 bar, and dry gas was at 1.0 L/min. The drying 
temperature was 180ºC. The instrument was calibrated using Tuning Mix (Agilent 
Technologies, Santa Clara, CA) as the external mass calibrant. The parameters for the 
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Waters Q-TOF instrument are listed below: The Z-Spray source was operated at 2.8 kV, 
the cone voltage was 150 V, and RF lens was 50. The source temperature and desolvation 
temperatures were 80ºC and 180ºC, respectively. The collision energy was 10 eV, and the 
MCP detector was 2,200 V. Protein samples were loaded on an Opti-Guard C18 column 
(10 mm × 1 mm i.d., Cobert Associates, St. Louis, MO) for desalting and then eluted to 
mass spectrometer using 50% (v/v) acetonitrile with 0.1% formic acid (FA) at 10 μL/min. 
Spectral deconvolution was performed using MaxEnt. 
 
Data Processing of NEM-Labeling (performed by Don Rempel, Washington 
University) 
A number of the equation parameters were extracted from the kinetic data by 
nonlinear least squares fitting of theoretical signals, computed from the parameter 
dependent system state trajectories, to experimental data. The system state was a vector 
that has the solution chemical species concentrations as the vector coordinates. In each 
trial of the search, the postulated parameters together with the system state of 
concentrations permitted the calculation of the time rate of change of the state by 
computing the fluxes into and out of each species as described by the system equations. 
This process implemented a vector first-order ordinary differential equation, which was 
solved by numerical integration for the time interval of reaction initiation to the longest 
reaction time to give the state time trajectory in each fitting trial. For comparison with the 
experiment data, the theoretical signal for each Ape1 species was computed as a fraction 
of all Ape1 species concentrations that were first weighted by a relative sensitivity factor 
that varied linearly with slope gN with the number of NEMs attached starting with one for 
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Δ40Ape1 by itself. The calculations were carried out in the computer application 
Mathcad 14.0 M010 (Parametric Technology Corporation, Needham, MA). The 
numerical integration of the differential equation was carried out by the adaptive fourth-
order Runge-Kutta function ―Rkadapt‖. 
 
Denatured Ape1 and ESI MS 
A sample of 10 µM FLApe was denatured by 2 M guandinium hydrochloride and 
incubated along with 70 µM NEM in 10 mM Tris pH 7.5 buffer. The guanidium 
hydrochloride was gradually dialyzed out in two steps reducing the concentration by 1 M 
in each step. This sample and an untreated native full-length Ape1 were then subjected to 
ESI analysis using an Agilent 6520 Q-TOF instrument. Deconvolution was done using 
Mass Hunter software that is part of that system.  
 
Results 
Initially, wtΔ40Ape1 and the 3 mutants (C99A, C138A, and C99A/C138A) were 
incubated with NEM and without E3330 to verify the labeling that would occur for Ape1 
untreated with E3330. wtΔ40Ape1 results in the formation of a +2 NEM modified 
species as indicated by a shift in mass of 250 Da (Figure 6A). The C99A and C138A 
show a reduction from +2 NEM for wtΔ40Ape1 to +1 NEM (Figure 6B and C), and for 
the double mutant there is no longer any NEM bound (Figure 6D). These products form 
within 30 s of the addition of NEM.   
A time course was done with wt that shows nearly 100% modification of 
wtΔ40Ape1 within 10 minutes at room temperature (Figure 7A). The time course shows 
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the gradual disappearance of the peaks corresponding to unmodified cysteines in the mass 
spectrum. Of the seven Cys residues within Ape1, only Cys 99 and Cys 138, the two 
solvent-accessible Cys residues, are labeled at room temperature. The C99A mutant and 
C138A mutant both show a reduction from +2 NEM for wtΔ40Ape1 to +1 NEM, and for 
the double mutant there is no longer any NEM bound. The sites of modification were 
verified by LC-MS/MS.  
When Δ40Ape1 was incubated with both NEM and E3330, the +2 NEM product 
again forms quickly. However, over time, a second major product corresponding to the 
addition of 7 NEMs was observed (Figure 7B). This peak is only seen in the presence of 
E3330. Trypsin digestion coupled with LC-MS/MS analysis conclusively indicates that 
the protein is modified on the five remaining cysteines, which were originally solvent-
inaccessible, and not on other reactive amino-acid residues. 
After a 6 h incubation of Δ40Ape1 with NEM , with and without E3330, a small 
amount of + 3 NEM product was observed (Figure 8); LC-MS/MS analysis indicates that 
this product comes from the NEM reaction with other, non-Cys, solvent-accessible sites 
(e.g., K, H, and the –NH2 at the terminus). 
To test whether the results of the Δ40Ape1/E3330/NEM experiment were caused 
by the DMSO, in which E3330 was dissolved, reactions of Δ40Ape1/NEM alone, with 
E3330, and with DMSO were incubated at 30 minutes and 4 hours and then analyzed by 
global ESI-MS (Figure 9). At 30 min, all three samples appeared identical with a +2 
NEM. At 4 hours, all samples still have the same +2 NEM peak; however, they also have 
a small +3 NEM peak. The E3330 sample also includes a +7 NEM peak.  
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To prove that E3330 did not just denature the protein, forming the +7 product, a 
sample of Ape1 with E3330 was incubated for 24 hr at room temp, followed with NEM 
at room temp for 0.5 hr. Only the +2 NEM product was observed, without any +7 NEM 
product. If E3330 were denaturing Δ40Ape1, we would have expected to modify all 7 
Cys residues with NEM.  
Also, to verify that there wouldn’t be NEM labeling higher than +7 NEM 
showing nonspecific binding, we did a denaturing experiment in which a sample of 10 
μM FLApe was denatured by 2 M GuHCL and treated with 70 μM NEM. For the 
untreated native FLApe sample (Figure 10A), the only major peak is the parent peak for 
full-length Ape1 labeled P with an observed mass of 35,641.3 (expected 35,641.5). The 
denatured NEM treated FLApe sample (Figure 10B) resulted in 4 major peaks including 
the parent peak labeled P, along with +5 (36,266.6), +6 (36,392.4), and +7 (36,517.3) 
NEM modifications to the parent molecule. No higher mass peaks for modification with 
NEM beyond +7 NEM were observed.  
Other than the slight presence of the +3 peak, there are no intermediates between 
+2 and +7 NEM. To see a gradual unfolding of Ape1, I took time points every 30 min for 
4 hrs of a sample of Ape1/E3330/NEM. At 30 min only the +2 NEM product was 
detected. But there is no gradual labeling of Cys residues. Around 3 hours, both +3 and 
+7 were detected. Over the same time period and temperature, no +7 NEM modified 
species formed in the reaction of Δ40Ape1 with NEM in the absence of E3330.  
However, what could be seen was the +2 NEM species decreasing over time 
while the +7 NEM product was increasing (Figure 7). The lack of intermediates even 
with a 5 molar excess of NEM suggest that there is a rapid conversion from the +2 to +7 
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NEM state once one or more of the five Cys residues remaining in the +2 NEM modified 
Δ40Ape1 reacts with another NEM. Analysis performed by LC-MS/MS confirmed that 
all seven Cys residues in the +7 NEM species were modified. As for the small amount of 
the +3 NEM species, there is no significant change in its quantity throughout the reaction. 
This leads us to the conclusion that it is not an intermediate that leads to the formation of 
the +7 NEM product. There is also an equal amount of this product observed without the 
addition of E3330.  
Based on these results, it is proposed that a rate-limiting step occurs after the 
rapid formation of the +2 NEM species, in which Ape1 undergoes a conformational 
change from fully folded to locally unfolded state (Figure 11). It is within this state that 
E3330 binds to and stabilizes Ape1, allowing the Cys residues to be exposed and then 
bound with NEM, so that we are able to observe the +7 NEM species.  
Up to this point, all samples had been incubated at room temperature. If the 
temperature was raised to 37ºC, we would expect to see the reaction time required to 
form the +7 NEM modified Δ40Ape1 decrease, and for this unfolded state to be observed 
without the addition of E3330. As shown in Figure 12A, Δ40Ape1 treated with NEM at 
37ºC without E3330 will form a small percentage of +7 NEM, supporting that the protein 
does undergo this conformation change. For the sample treated with E3330 (Figure 12B), 
the time for the +7 NEM product to appear decreased from 3 hours to 30 minutes. This 
decrease in time shows that Ape1 adopts the locally unfolded state, thus establishing an 
equilibrium for the 2 conformations. 
It was of interest to determine whether or not any specific cysteines were required 
in order for Ape1 to undergo this conformational change. Because of the importance of 
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C65 in Ape1 redox function, is it required for Ape1 to adopt an alternate conformation? 
Or is the modification of the 2 solvent accessible cysteines, 99 and 138, required for the 
remaining cysteines to be labeled? The following mutants were made for Δ40Ape1: 
C65A, C99A, C138A, C99A/C138A. They were incubated with NEM and E3330 then 
analyzed by global ms. All mutants were observed to undergo a conformational change 
that allowed for the remaining cysteines to be modified (Figure 13). This result indicates 
that labeling of the buried Cys residues in Δ40Ape1 does not depend on the presence of 
Cys 65, Cys 99, or Cys 138.  
 
Discussion 
Additional Studies 
To further test our hypothesis that E3330 interacts with a locally unfolded form of 
hApe1, maintaining it in a more opened form, and that this leads to the Δ40Ape1+7 NEM 
adduct, we relied on our collaborators to perform hydrogen/deuterium exchange (HDX) 
experiments to analyze the exchange of amide protons with deuterium in different 
adducts of Ape1. If our hypothesis is correct, then we should be able to see differences in 
the extent of HDX for the Δ40Ape1+7 NEM adduct in comparison with the Δ40Ape1+2 
NEM adduct. Furthermore, if the Δ40Ape1+3 NEM adduct is a ―dead end‖ as we 
proposed, its extent of HDX should match that of the Δ40Ape1+2 NEM adduct.  
As reported (45) the +2 NEM adduct exchanges 144 amide hydrogens whereas for 
the Δ40Ape1+7 NEM adduct, the corresponding number of exchanges is 188. With a 
kinetic model reported earlier (62), the data was fitted and the exchanging amides were 
categorized into the number of fast, intermediate, and slow.  
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Based on the model, we were able to assign the number of amide protons of each 
type. The results: 
Table 1 Hydrogen/Deuterium Exchange Results 
  Fast Intermediate Slow 
ApeΔ40 78 ± 2 25 ± 4 43 ± 1 
ApeΔ40 + 2 NEM 81± 1 20 ± 4 43 ± 2 
Ape Δ40 + 3 NEM 81 ± 2 19 ± 2 41 ± 1 
Ape Δ40 + 7 NEM 136 ± 3 14 ± 1 38 ± 4 
 
The number of fast exchanging adducts has increased substantially for the unfolded 
conformation as a result of the reaction with NEM. Δ40Ape1+7 NEM has 40 more 
exchanging amide H’s than Δ40Ape1/ Δ40Ape1+2 NEM/ Δ40Ape1+3 NEM, which 
supports the existence of a locally unfolded form. Considering that there are 278 total 
amide hydrogens in the protein, we see that only 68% underwent exchange even for the 
protein modified with seven NEMs, indicating that Δ40Ape1+7 NEM form is a partially 
unfolded form and not a completely denatured one. The HDX results for Δ40Ape1, 
Δ40Ape1+2 NEM and Δ40Ape1+3 NEM proteins are similar, confirming that these three 
species have the same conformation, and that additions of NEM to the solvent accessible 
Cys residues and to other reactive sidechains do not change the conformation of 
Δ40Ape1. 
 Our collaborators also performed LC-MS/MS to examine disulfide bond 
formation (45). Considering the requirement of Cys65 for redox, the Cys65 would serve 
as the nucleophilic thiol in the reduction of transcription factors by Ape1. For this thiol-
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mediated disulfide exchange reaction to occur, it must exist in a reduced state. This 
would be monitored by looking at disulfide bonds and the effect of E3330 on their 
formation. LC-MS/MS analysis of tryptic peptides showed an increase of disulfide bonds 
when treated with E3330. Table 2 shows the percent of disulfide bonds for the bonds 
listed: 
Table 2 Disulfide Bonds Formed 
  
% No 
E3330 
%With 
E3330 
C65-C93 0.16 8.2 
C93-C99 0.04 5.8 
C93-C138 0.01 2.6 
C65-C99 0.01 2.6 
 
Both Cys65 and Cys93 play an important role in the redox activity of Ape1(29, 31), and 
so formation of disulfide bonds C65-C93, C65-C99, and C93-C99 would be expected to 
impact the redox activity of Ape1.  
  
Combining the Data 
With all data considered, we can conclusively say that Ape1 requires a 
conformational change in order to obtain the +7 NEM adduct. When incubated with 
E3330 or placed under elevated temperature conditions, the locally unfolded form of the 
+2 NEM state of Ape1 is sufficiently long-lived that it can be captured by reaction with 
NEM to give a +7 NEM modified Ape1. In the reaction for the +2 NEM state, the NEM 
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bond is irreversible (Figure 11), and the slow step of the reaction is the local unfolding of 
the +2 NEM modified Ape1. E3330 does not create this unfolding, but drives the 
equilibrium toward the unfolded form. It’s in this unfolded state of Ape1 that some 
previously buried Cys residues are accessible and able to react with NEM producing the 
+7 NEM species. By chemical footprinting with NEM in the presence and absence of 
E3330, we see evidence for a locally unfolded state of Ape1 through these newly exposed 
and labeled cysteines. 
This chemical footprinting combined with the HDX kinetics gives strong 
evidence for the existence of a partially or locally unfolded conformation of Ape1. The 
HDX experiments, as determined by mass spectrometry, show an increase of 
approximately 40 deuterium atoms in the +7 NEM adduct when compared to both the 
native Ape1 and +2NEM adduct. The unfolding in our experiments helps us to explain 
the exposure for the buried residue Cys65, which was previously shown to be a necessity 
for redox function. 
In our search for understanding the mechanism by which E3330 inhibits the redox 
activity of Ape1, we propose that E3330 interacts with the locally unfolded state of Ape1, 
stabilizing it so that the normally buried Cys residues can react with NEM. In shifting the 
equilibrium toward the locally unfolded state of Ape1, E3330 also increases disulfide 
bond formation in Ape1. This increase could be due to a stabilization of the unfolded 
conformation by E3330 or due to a reversible modification of Cys residues, making them 
susceptible to nucleophilic attack by a sylfhydryl and thereby resulting in disulfide bond 
formation.  
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CHAPTER III 
E3330 Analog Studies 
 
Introduction to the E3330 analogues 
It’s been shown in previous studies that E3330 binds specifically to Ape1. E3330 
blocks Ape1’s redox function with transcription factors by not allowing them to be 
converted from an oxidized to a reduced state, therefore preventing them from binding to 
their target DNA (44, 46). Also, E3330 blocks angiogenesis in in vitro and in vivo models 
(43, 44, 63). 
The need for an E3330 analog is to develop a more efficient and effective 
compound that would allow for sub-micromolar levels of activity (E3330 requires a 
micromolar amount), and to gain perspective on the mechanism or mechanisms of 
E3330’s inhibition of Ape1’s redox function. 
Results of synthesis of E3330 analogs (Figure 14) were recently published (46), 
and further investigation was performed on the 3 most promising ones: RN8-51, RN10-
52, and RN7-60 (64). Using EMSA (electrophoretic mobility shift assay) (44) with AP-1 
as the transcription factor target, these analogs blocked the redox function of Ape1. Also, 
their IC50’s were at least ten times lower than E3330. E3330 had an IC50 of 20 µM 
where as RN8-51, RN10-52, and RN7-60 were 0.5, 0.75, and 1.5 µM respectively (64).  
From a recent publication (64), studies were performed in order to examine the 
specificity of the compounds with Ape1. The EMSA studies were repeated substituting 
thioredoxin, a cellular redox protein, for Ape1. Thioredoxin has been shown to reduce 
AP-1 in vitro. These studies concluded that increasing the amounts of E3330, RN8-51, 
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and RN10-52 decreased the binding of AP-1 to DNA by blocking the ability of Ape1 to 
reduce AP-1, but did not similarly inhibit reduction by thioredoxin. RN7-60 affected both 
Ape and thioredoxin. Though it affects Ape1 at greater levels, it is not an Ape1-specific 
redox inhibitor. As for E3330, RN10-52, and RN8-51, they only affect Ape1, and 
therefore are Ape1-specific redox inhibitors. 
This study also proved that the analogs are specific to Ape1’s redox function and 
do not affect it’s DNA repair function, as also seen with E3330 previously (44, 65). None 
of the analogs blocked Ape1 repair endonuclease activity, supporting that they are 
specific to redox function. 
Cell-based transactivation assays were performed to test whether the redox 
function would be blocked in cells with analogs as it was for E3330 (1). Using SKOV-3x, 
an ovarian cell line, NF-ĸB binding sequence upstream of a luciferase reporter was 
expressed. NF-ĸB was dose-dependently unable to bind with an increasing amount of 
E3330 and analogs. Their IC50s were 80, 27, 12, and 25 µM for E3330, RN8-51, RN10-
52, and RN7-60, respectively. This also shows the better functionality of the analogs in 
cells in comparison to E3330.  
With proof that these redox-inhibiting analogs have lower IC-50 values than 
E3330, for both in vitro and in cell-based studies, we wanted to further examine the 
interaction they have with Ape1 using mass spectrometry analysis in hopes of gaining 
insight into how the reaction occurs.  
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Materials and Methods 
Compounds 
E3330 and its analogs (RN8-51, RN10-52, and RN7-60) were synthesized as 
previously described (44, 46).  
 
Expression and purification of proteins 
wtΔ40APE1 
 As described in Chapter II Materials and Methods. 
Full-length APE1 
To express and purify full-length Ape1 (FL-Apr1), an N-terminal hexa-His- 
SUMO-fusion (Invitrogen, Rockville, MD) was constructed. The fusion construct was 
transformed into Rosetta (DE3) E. coli (Novagen, Gibbstown, NJ), grown in 3 L of LB 
media with 20 µg/mL kanamycin and 34 µg/mL chloramphenicol until the OD at 600 nm 
reached 0.6, and then induced overnight with 1 mM isopropyl thiogalactoside at 15ºC. 
The cultures were harvested by centrifugation at 4000 x g for 30 min, and the pellets 
were stored at -80ºC. Each cell pellet was resuspended in 20 mL of 50 mM sodium 
phosphate buffer pH 7.8, 0.3 M NaCl, 10 mM imidazole, and then lysed by using a 
French press (SLM-AMINCO: Spectronic Instruments, Rochester, USA) at 1000 psi. The 
suspension was centrifuged at 35,000 rpm for 35 min, and the supernatant was then 
loaded on a Ni-NTA column at 4ºC. The column was washed with 20 column volumes of 
50 mM sodium phosphate buffer pH 7.8, 0.3 M NaCl, 20 mM imidazole protein and then 
incubated overnight with the SUMO-specific protease Ulp1 added at a molar ratio of ~ 
1:1000 (Ulp1: FL APE1). Full-length APE1 was then eluted from the column in the same 
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buffer and further purified using an S-Sepharose column (GE Healthcare, Piscataway, 
NJ) run in 50 mM MES pH 6.5, 1 mM DTT, and a linear NaCl gradient (0.05-1 M). The 
peak fractions were then combined, concentrated, and subjected to gel filtration 
chromatographic separation using a Superdex 75 (GE Healthcare, Piscataway, NJ) in 50 
mM Tris pH 8.0, 0.1 M NaCl. Fractions containing full-length APE1 were then 
concentrated using Amicon Ultra centrifugal concentrators (Millipore, Billerica, MA) and 
stored at -80ºC.  
 
Mass Spectrometric Analysis 
Global ESI-QTOF Experiments 
Protein samples were analyzed in the positive-ion mode on a Bruker MaXis UHR-
TOF (ultra-high resolution time-of-flight) (Bruker Corp., Fremont, CA). Capillary 
voltage was set at -3600 V. Nebulizer pressure was 0.4 bar, and dry gas was at 1.0 L/min. 
The drying temperature was 180ºC. The instrument was calibrated using Tuning Mix 
(Agilent Technologies, Santa Clara, CA) as the external mass calibrant. Spectral 
deconvolution was performed using MaxEnt with Data Analysis (provided by the 
manufacturer of the spectrometer). Reactions of protein and redox inhibitors were carried 
out at a 1:5 molar ratio of protein (100 μΜ) to ligands (500 μΜ) in 10 mM HEPES 
(Sigma, St. Louis, MO) buffer at pH 7.5 at room temperature. Reactions were quenched 
on dry ice before mass spectrometry (MS) analysis. Typically, 200-300 pmol of protein 
samples were loaded on an Opti-Guard C18 column (10 mm × 1 mm i.d.; (Cobert 
Associates, St. Louis, MO) for desalting and then eluted to mass spectrometer using 50% 
(v/v) acetonitrile with 0.1% formic acid (FA) at 10 μL/min.  
27 
 
LC-MS/MS Experiments 
A 10 μL solution of APE1 (100 µM) and RN6-70, RN10-52 or RN8-51 (500 µM) 
was incubated in 10 mM HEPES (pH 7.5) at room temperature for 0.5 h. DTT 
(protein/DTT = 1/20, mol/mol) was added to quench the reaction. The sample was diluted 
with water to a final concentration of 1 µM. A portion of the final diluted solution (50 
µL) was submitted to trypsin digestion (protein/trypsin = 50/1, w/w) at 37ºC for 4 h. The 
solution was then analyzed by LC-MS/MS, whereby 5 µL of digestion solution was 
consumed for each experiment. Reversed-phase capillary LC separations were performed 
with an Eksigent NanoLC-1D pump (Eksigent Technologies Inc., Livermore, CA). The 
reversed-phase capillary column (0.075 mm × 150 mm) was packed in house by using a 
PicoFrit
TM
 tip (New Objective Inc., Woburn, MA) with Magic C18 resin (5 μm particles, 
200 Å pore size, Michrom Bioresources Inc., Auburn, CA). The mobile phases consisted 
of water with 0.1% FA (A) and acetonitrile with 0.1% FA (B). Immediately after sample 
loading, the mobile phase was held at 98% A for 12 min. A linear gradient was 
performed by using 2% to 60% solvent B over 60 min, then to 80% solvent B over 10 
min at 260 nL/min, followed by a 12 min re-equilibration step by 100% solvent A. The 
flow was directed by a PicoView Nanospray Source (PV-550, New Objective Inc., 
Woburn, MA) to the LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific Inc., 
San Jose, CA). The spray voltage was 1.8-2.2 kV, and the capillary voltage was 27 V. 
The conventional data-dependent MS/MS acquisition method was employed using the 
Xcalibur 2.0.7 control system, in which full spectra were collected over the range of m/z 
350–2000 followed by product-ion (MS/MS) spectra of the six most abundant ions. The 
full mass spectra of the peptides were acquired at high mass resolving power (60,000 for 
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ions of m/z 400) with the FT analyzer. The six most abundant precursor ions were 
dynamically selected in the order of highest to lowest intensity (minimal intensity of 
1000 counts) and subjected to collision-induced dissociation (CID) at a normalized 
collision energy of 35% of the maximum available. Precursor activation was performed 
with an isolation width of 2 Da and an activation time of 30 ms. The automatic gain 
control target value was regulated at 1 x 10
6
 for FT and 3 x 10
4
 for the ion trap, with a 
maximum injection time of 1000 ms and 200 ms for the FT and the ion trap, respectively. 
The instrument was externally calibrated by using a standard calibration mixture of 
caffeine, the peptide MRFA, and Ultramark 1621 (Thermo Fisher Scientific). To identify 
covalent modifications, LC-MS/MS data were searched with Mascot 2.2 (Matrix Science, 
London, UK). Parameters used for Mascot were: enzyme, trypsin; maximum missed 
cleavage, 3; peptide mass tolerance, 10 ppm with one 
13
C peak; peptide charge, +1 to +3; 
product mass tolerance, 0.6 Da; instrument type, default (searching for all types of b and 
y ions). 
 
Results 
These studies were carried out in collaboration with Michael Gross’s Lab at 
Washington University St. Louis, specifically by Dian Su, Ph.D. We used ESI-MS to 
study E3330 and its analogs in a reaction with Ape1. In the experiments for FLApe1 
protein, we incubated a mixture of RN7-60, RN10-52, RN8-51, and E3330, all at a 5 
molar excess, for 1 minute with FLApe1. Our results, (Figure 15), show that both RN7-
60 and RN10-52 form covalent adducts, but the other compounds do not. Based on the 
masses for RN7-60 (276 Dalton) and RN10-52 (319 Dalton) a peak shift of 240 Da and 
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283 Da, respectively, was seen. This difference in mass is due to the loss of HCl (36 Da) 
in order for a covalent reaction to occur. These analogs are the most reactive of the group, 
able to bind within a 1 minute time frame, and they have similar peak intensities.  
 Both analogs were individually tested by a 30 minute incubation with FLApe1 
(Figure 16A and B). Both reactions showed all 7 cysteines to be modified, and peaks for 
+1 to +7 adducts were found as analyzed by LC-MS/MS following tryptic digestion.  
Analog RN8-51 was further analyzed in a reaction with FLApe1 for 1 hour 
(Figure 16C). It only caused a partial modification; about 50% of the protein had a single 
cysteine modified, and 20% had a double modification. The peak shifts of 274 Da (RN8-
51 has a weight of 272 Da) leads us to believe that there is no loss of substituent moieties. 
LC-MS/MS was again performed, and with no resulting modified peptides, we conclude 
the modifications that were made are reversible.  
Δ40Ape1 was also tested with each compound individually with similar results: 
RN7-60 had +2, +3, +4, and +5 cysteines modified, RN10-52 had +2 and +3 
modifications, RN8-51 only had one modification. For both FLApe1 and Δ40Ape1, with 
E3330 (Figure 16D) no modifications were observed. 
To further probe the modifications made by RN8-51, 3 mutant forms of Δ40Ape1 
were used: C99A, C138A, and C99A/C138A. These were used to determine if the 
modifications were only with solvent access cystienes. The samples were incubated for 3 
hours before being analyzed by global MS. The double mutant had no modifications, but 
both single mutants had one modification each. This conclusively shows that the 
modifications are only occurring on the surface. 
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Discussion 
Our results show that both RN7-60 and RN10-52 react quickly with Ape1 to form 
covalent adducts. All cysteines are subject to modification, and we were able to see +1 to 
+7 additions of these analogs to Ape1. RN8-51 only binds to the two solvent accessible 
cysteines (C99 and C138), and these are reversible modifications. No modifications were 
present for E3330. Similar results were obtained for both FLApe1 and Δ40Ape1.  
In looking at Figure 17, we justify RN7-60 and RN10-52 having a more rapid 
Michael addition reaction because chlorine is a better leaving group, and they are able to 
form a covalent bond. For RN8-51, the methoxy group is a poorer leaving group than the 
protein thiolate, allowing the reaction to revert and making the modifications reversible.  
We can conclude from this data that RN7-60 and RN10-52 are modifying more 
than just the solvent accessible cysteines, and so an unfolding of Ape1 must occur to 
expose the buried cysteines to the compounds.  
As for RN8-51, it appears to behave more like E3330, forming reversible adducts 
with Ape1. But, in conjuction with other data (64), it has a lower IC50. Along with its 
specificity to Ape’s redox function, this analog is proving to be a compound of interest 
for further examination in use for anti-cancer therapeutic development.  
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CHAPTER IV 
Conclusion 
      
In an effort to develop a novel cancer therapeutic, Ape1 is an attractive target 
because it has two important functions, BER and redox. Our research focused on the 
redox function of Ape1, which would prevent cell proliferation. Other studies have 
shown that intracellular redox could be used as regulator of growth in cancer cells (35). 
Regulation of the intracellular redox environment is critical for cell viability and 
maintenance of cellular homeostasis. An Ape1 deficient human cell line cannot be 
generated because Ape1 is essential for early embryonic development (39). Therefore, 
identification and development of a specific inhibitor of this protein will significantly 
help as a tool in Ape1 functional study and therapeutic potential.  
Our studies, divided into two parts, examined the inhibitors that block Ape1 redox 
function. The first section uses E3330 because of its ability to kill a variety of cancer 
cells without significantly affecting normal cells (44). Using this inhibitor, we conducted 
a series of experiments to examine the Ape1 redox mechanism. 
We developed a chemical footprinting/mass spectrometric assay using to 
characterize the interaction of the redox inhibitor, E3330, with Ape1. Our results show an 
interaction between E3330 and Ape1 and allow us to conclude that Ape1 requires a 
conformational change in order to obtain the +7 NEM adduct. This chemical footprinting 
combined with the HDX kinetics gives strong evidence for the existence of a partially or 
locally unfolded conformation of Ape1. The unfolding in our experiments helps us to 
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explain the exposure for the buried residue Cys65, which was previously shown to be 
required for redox function. 
In our search for understanding the mechanism by which E3330 inhibits the redox 
activity of Ape1, we propose that E3330 interacts with the locally unfolded state of Ape1, 
stabilizing it so that the normally buried Cys residues can react with NEM in our 
experiments. In shifting the equilibrium toward the locally unfolded state of Ape1, E3330 
also increases disulfide bond formation in Ape1. This increase could be due to a 
stabilization of the unfolded conformation by E3330 or due to a reversible modification 
of Cys residues, making them susceptible to nucleophilic attack by a sylfhydryl and 
thereby resulting in disulfide bond formation.  
The third chapter includes a characterization of analog compounds of E3330: 
RN7-60, RN8-51, and RN10-52. These compounds were in a recent publication (46), and 
further investigation was necessary to determine their value as redox inhibitors and to 
assess whether they were an improvement over E3330. The analogs also provide further 
information regarding Ape1’s redox function. 
Other studies have shown that these redox-inhibiting analogs have lower IC-50 
values than E3330, for both in vitro and in cell-based studies. We can conclude from this 
data that RN7-60 and RN10-52 are modifying more than just the solvent accessible 
cysteines, and so an unfolding of Ape1 must occur to expose the buried cysteines to the 
compounds.  
 And for RN8-51, it appears to behave more like E3330, forming reversible 
adducts with Ape1. But, in conjuction with other data (64), it has a lower IC50. Along 
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with its specificity to Ape’s redox function, this analog is proving to be a compound of 
interest for further examination in use for anti-cancer therapeutic development.  
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Figure 1 BER pathway. Ape1 is the AP endonuclease that cleaves abasic sites in the 
second step of the Base Excision Repair pathway.
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Figure 2 Ape1’s role in BER pathway. Figure from Tainer, J. et al Nature 403 (6768): 
451–456. Ape1 plays a critical role in the BER DNA repair pathway as an AP 
endonuclease, which processes the AP sites. Ape1’s role in the BER pathway begins 
when the Ape1 enzyme creates a nick in the phosphodiester backbone at a abasic 
(baseless) site through acyl substitution. The Asp210 residue deprotonates a water 
molecule, which then performs a nucleophilic attack on the phosphate group located 5´ to 
the AP site. Electrons from an oxygen atom in the phosphate group moves down, freeing 
a 5´ phosphate group on the AP site and a 3´-OH on the normal nucleotide, both of which 
are stabilized by the Mg
2+
 ion. 
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Figure 3 Ape1’s role in redox of transcription factors. Through its redox function, 
Ape1 regulates gene expression by modifying the redox status of some transcription 
factors which are involved in variety of cancer processes. The redox control of 
transcription factors alters gene expression, leading to cell survival or cell death.  
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Figure 4 X-ray crystal structure of Ape1. X-ray crystal structure of hApe1 with seven 
cysteines shown. C99 and C138 are surface accessible, whereas C65, C93, C208, C296, 
and C310 are buried. C65 is thought to be essential in the redox function of the protein. 
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Figure 5 Chemical structures of E3330 and NEM. 
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Figure 6 ESI mass spectra wtΔ40Ape1 and mutants with NEM labeling. wtΔ40Ape1 
and the 3 mutants (C99A, C138A, C99A/C138A) were incubated with NEM and without 
E3330 to verify the labeling that would occur for Ape1 untreated with E3330. 
wtΔ40Ape1 results in the formation of a +2 NEM modified species as indicated by a shift 
in mass of 250 Da (A). The C99A and C138A show a reduction from +2 NEM for 
wtΔ40Ape1 to +1 NEM (B and C), and for the double mutant there is no longer any 
NEM bound (D). These products form within 30 s of the addition of NEM.   
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Figure 7 Kinetics of wtΔ40Ape1 with E3330 and NEM. Kinetics of wtΔ40Ape1 
reaction with NEM (A) or NEM and E3330 (B). Both samples were prepared in 10 mM 
HEPES at pH 7.5 at RT ([protein] = 100 µM; [E3330] = [NEM] = 500 µM). Aliquots 
were quenched with DTT at various times. Mass spectra were collected on a Bruker 
MaXis UHR-TOF instrument, and deconvolution was done with MaxEnt1 algorithm 
provided with that system. The sums of intensities of different NEM adducts of 
Δ40APE1 were normalized to 1. Data were fitted with Mathcad using a relatively straight 
forward one-parameter fit of the +2 NEM adduct kinetic curves and a three parameter fit 
varying k
slow
NEM , kON, and gN  was used to fit the +7 NEM adduct kinetic curves. 
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Figure 8 ESI mass spectra of wtΔ40Ape1 with E3330 and NEM. ESI mass spectra of 
wtΔ40Ape1 after incubation without (A) and with E3330 (B) in the presence of NEM for 
30 min (left panel) and 6 h (right panel). Samples were incubated in 10 mM HEPES with 
150 mM KCl at pH 7.5([protein] = 100 µM; [E3330] = [NEM] = 500 µM). The symbol * 
denotes peaks for the water adducts. Mass spectra were collected on a Waters Micromass 
Q-TOF instrument and deconvolution was done with MaxEnt1 algorithm provided with 
that system. 
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Figure 9 ESI mass spectra of wtΔ40Ape1 at 30 min and 4 hr. ESI mass spectra of 
reactions with (A) wtΔ40Ape1/NEM alone, (B) with E3330, and (C) with DMSO were 
incubate at 30 minutes and 4 hour then analyzed on a Waters Micromass Q-TOF 
instrument and deconvolution was done with MaxEnt1 algorithm provided with that 
system. At 30 min, all three samples appeared identical with a +2 NEM. At 4 hours, all 
samples still have the same +2 NEM peak; however, they also have a small +3 NEM 
peak. The E3330 sample also includes a +7 NEM peak.  
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Figure 10 ESI mass spectra of denatured FLApe with NEM. ESI mass spectra of 
untreated native full-length Ape1 (A) and denatured full-length Ape1 treated with NEM 
(B). In (A), the only major peak is the parent peak for full-length Ape1 labeled P with an 
observed mass of 35,641.3 (expected 35,641.5). Treatment of denatured Ape1 (B) 
resulted in 4 major peaks including the parent peak labeled P, along with +5 (36,266.6), 
+6 (36,392.4), and +7 (36,517.3) NEM modifications to the parent molecule. No higher 
mass peaks for modification with NEM beyond +7 NEM were observed.  
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Figure 11 Scheme of Ape1 unfolding. The reaction of wtΔ40Ape1 with NEM in the 
presence or absence of E3330 involves several intermediates. The initial reaction of 
wtΔ40Ape1 with NEM is rapid for the +2 NEM molecules. Then there is a slower 
reaction to modify all seven Cys residues of wtΔ40Ape1. The rate-limiting step for the 
reaction is a conformational change of the +2 NEM species from a fully folded state to a 
locally unfolded state. E3330 then binds to and stabilizes this locally unfolded state, 
allowing the exposure of one or more buried Cys residues. These exposed residues can 
then react with NEM, leading to the +7 NEM modified species. 
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Figure 12 ESI mass spectra wtΔ40Ape1 increased temperature. ESI mass spectra of 
wtΔ40Ape1 without and with incubation with E3330 in the presence of NEM for 0.5 h at 
37 ºC. Sample was incubated in 10 mM HEPES at pH 7.5 ([protein] = 10 µM; [E3330] = 
[NEM] = 50 µM). Mass spectrum was collected on a Bruker MaXis UHR-TOF 
instrument and deconvolution was done with MaxEnt1 algorithm.  
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Figure 13 ESI mass spectra of hΔ40Ape1 mutants. ESI mass spectra of C65A 
Δ40Ape1 without (A) and with incubation with E3330 (B) in the presence of NEM for 12 
h. (C) ESI mass spectra of C99A/C138A Δ40Ape1 incubated with E3330 and NEM for 
12 h. Samples were incubated in 10 mM HEPES at pH 7.5 ([protein] = 100 µM; [E3330] 
= [NEM] = 500 µM). The symbol * denotes water adducts. Mass spectra were collected 
on a Waters Micromass Q-TOF instrument and deconvolution was done with MaxEnt1 
algorithm that was part of that system. 
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Figure 14 Chemical structures of E3330 analogs: RN7-60b, RN10-52, and RN8-51. 
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Figure 15 ESI mass spectra of FLApe1 and all E3330 compounds. ESI spectrum of 
FL-Ape1 and mixture of ligands (RN7-60, RN10-52, RN8-51, and E3330) after 1-min 
reaction showing modifications by RN7-60 and RN10-52. P stands for FL-APE1; * 
indicates the water adducts of the protein and ligand complexes. 
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Figure 16 ESI mass spectra of FLApe1 and analogs showing modification. ESI 
spectra of FL-Ape1 and (A) RN7-60 and (B) 10-52 after 0.5-h reaction showing multiple 
(1, 2, 3, 4, 5, 6, and 7) modifications. (C) ESI spectra of FL-Ape1 and RN8-51 after 1-h 
reaction showing 1 and 2 modifications. (D) ESI spectra of FL-Ape1 and E3330 after 2-
hour reaction showing no modifications by E3330. P stands for FL-Ape1; * indicates the 
water adducts of the protein and ligand complexes; # indicates the contamination peaks 
due to the carry-overs on the C18 guard column. ^ indicates unidentified peaks.  
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Figure 17 Mechanism of covalent vs. reversible inhibition of Ape1 redox activity. 
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